CISH is induced during DC development and regulates DC-mediated CTL activation

European Journal of Immunology

Volumn 42, Issue 1, 2012, Pages 58-68

  Miah, Mohammad Alam ^a   Yoon, Cheol Hee ^a   Kim, Joonoh ^a   Jang, Jinah ^b   Seong, Young Rim ^b   Bae, Yong Soo ^a,b  

^a Sungkyunkwan University   (South Korea)

^b CreaGene Research Institute   (South Korea)

Author keywords

CISH; Cytotoxic T lymphocyte (CTL); Differentiation; Immunotherapy; Type 1 DC

Indexed keywords

CYTOKINE; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING CISH; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL CYCLE; CELL CYCLE ARREST; CELL MATURATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; LYMPHOCYTE PROLIFERATION; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANIMALS; APOPTOSIS; DENDRITIC CELLS; DOWN-REGULATION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS I; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; RNA, SMALL INTERFERING; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84855235676     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141846     Document Type: Article

References (41)

1. Blander, J. M. and Medzhitov, R., Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006. 440: 808-812.
2. Geissmann, F., Manz, M. G., Jung, S., Sieweke, M. H., Merad, M. and Ley, K., Development of monocytes, macrophages, and dendritic cells. Science 2010. 327: 656-661.
3. Spranger, S., Javorovic, M., Burdek, M., Wilde, S., Mosetter, B., Tippmer, S., Bigalke, I. et al., Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J. Immunol. 2010. 185: 738-747.
4. Wesa, A., Kalinski, P., Kirkwood, J. M., Tatsumi, T. and Storkus, W. J., Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J. Immunother. 2007. 30: 75-82.
5. Hokey, D. A., Larregina, A. T., Erdos, G., Watkins, S. C. and Falo, L. D., Jr., Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res. 2005. 65: 10059-10067.
6. Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S. and Steinman, R. M., Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992. 176: 1693-1702.
7. Dijkers, P. F., van Dijk, T. B., de Groot, R. P., Raaijmakers, J. A., Lammers, J. W., Koenderman, L. and Coffer, P. J., Regulation and function of protein kinase B and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptor. Oncogene 1999. 18: 3334-3342.
8. Sebastian, C., Serra, M., Yeramian, A., Serrat, N., Lloberas, J. and Celada, A., Deacetylase activity is required for STAT5-dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells. J. Immunol. 2008. 180: 5898-5906.
9. Wierenga, A. T., Vellenga, E. and Schuringa, J. J., Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels. Mol. Cell. Biol. 2008. 28: 6668-6680.
10. Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., Hara, T. and Miyajima, A., A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 1995. 14: 2816-2826.
11. Matsumoto, A., Masuhara, M., Mitsui, K., Yokouchi, M., Ohtsubo, M., Misawa, H., Miyajima, A. and Yoshimura, A., CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997. 89: 3148-3154.
12. Ram, P. A. and Waxman, D. J., SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem. 1999. 274: 35553-35561.
13. Matsumoto, A., Seki, Y., Kubo, M., Ohtsuka, S., Suzuki, A., Hayashi, I., Tsuji, K. et al., Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol. Cell. Biol. 1999. 19: 6396-6407.
14. Li, S., Chen, S., Xu, X., Sundstedt, A., Paulsson, K. M., Anderson, P., Karlsson, S. et al., Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J. Exp. Med. 2000. 191: 985-994.
15. Khor, C. C., Vannberg, F. O., Chapman, S. J., Guo, H., Wong, S. H., Walley, A. J., Vukcevic, D et al., CISH and susceptibility to infectious diseases. N. Engl. J. Med. 2010. 362: 2092-2101.
16. Ketteler, R., Moghraby, C. S., Hsiao, J. G., Sandra, O., Lodish, H. F. and Klingmuller, U., The cytokine-inducible Scr homology domain-containing protein negatively regulates signaling by promoting apoptosis in erythroid progenitor cells. J. Biol. Chem. 2003. 278: 2654-2660.
17. Sakamoto, K., Creamer, B. A., Triplett, A. A. and Wagner, K. U., The Janus kinase 2 is required for expression and nuclear accumulation of cyclin D1 in proliferating mammary epithelial cells. Mol. Endocrinol. 2007. 21: 1877-1892.
18. Lehtonen, A., Matikainen, S., Miettinen, M. and Julkunen, I., Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation. J. Leukoc. Biol. 2002. 71: 511-519.
19. Perotti, C., Liu, R., Parusel, C. T., Bocher, N., Schultz, J., Bork, P., Pfitzner, E. et al., Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res. 2008. 10: R94.
20. Choi, Y. E., Yu, H. N., Yoon, C. H. and Bae, Y. S., Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter. Eur. J. Immunol. 2009. 39: 858-868.
21. Naka, T., Fujimoto, M., Tsutsui, H. and Yoshimura, A., Negative regulation of cytokine and TLR signalings by SOCS and others. Adv. Immunol. 2005. 87: 61-122.
22. Ilangumaran, S., Ramanathan, S. and Rottapel, R., Regulation of the immune system by SOCS family adaptor proteins. Semin. Immunol. 2004. 16: 351-365.
23. Yoshimura, A., Naka, T. and Kubo, M., SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 2007. 7: 454-465.
24. Sarna, M. K., Ingley, E., Busfield, S. J., Cull, V. S., Lepere, W., McCarthy, D. J., Wright, M. J. et al., Differential regulation of SOCS genes in normal and transformed erythroid cells. Oncogene 2003. 22: 3221-3230.
25. Jin, P., Wang, E., Provenzano, M., Deola, S., Selleri, S., Ren, J., Voiculescu, S. et al., Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J. Transl. Med. 2006. 4: 26.
26. Kovanen, P. E. and Leonard, W. J., Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 2004. 202: 67-83.
27. Ilaria, R. L., Jr., Hawley, R. G. and Van Etten, R. A., Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 1999. 93: 4154-4166.
28. Kotecha, N., Flores, N. J., Irish, J. M., Simonds, E. F., Sakai, D. S., Archambeault, S., Diaz-Flores, E. et al., Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 2008. 14: 335-343.
29. Vani, J., Kaveri, S. V. and Bayry, J., CISH and susceptibility to infectious diseases. N. Engl. J. Med. 2010. 362: 2092-2101.
30. Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J. and Carbone, F. R., T cell receptor antagonist peptides induce positive selection. Cell 1994. 76: 17-27.
31. Lim, D. S., Kim, J. H., Lee, D. S., Yoon, C. H. and Bae, Y. S., DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors. Cancer Immunol. Immunother. 2007. 56: 1817-1829.
32. Hill, J. A., Ichim, T. E., Kusznieruk, K. P., Li, M., Huang, X., Yan, X., Zhong, R. et al., Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J. Immunol. 2003. 171: 691-696.
33. Shen, L., Evel-Kabler, K., Strube, R. and Chen, S. Y., Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 2004. 22: 1546-1553.
34. Hawkins, E. D., Hommel, M., Turner, M. L., Battye, F. L., Markham, J. F. and Hodgkin, P. D., Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data. Nat. Protoc. 2007. 2: 2057-2067.
35. Quah, B. J., Warren, H. S. and Parish, C. R., Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat. Protoc. 2007. 2: 2049-2056.
36. Haeryfar, S. M., Conrad, D. M., Musgrave, B. and Hoskin, D. W., Antibody blockade of Thy-1 (CD90) impairs mouse cytotoxic T lymphocyte induction by anti-CD3 monoclonal antibody. Immunol. Cell Biol. 2005. 83: 352-363.
37. Hasbold, J., Gett, A. V., Rush, J. S., Deenick, E., Avery, D., Jun, J. and Hodgkin, P. D., Quantitative analysis of lymphocyte differentiation and proliferation in vitro using carboxyfluorescein diacetate succinimidyl ester. Immunol. Cell Biol. 1999. 77: 516-522.
38. Yoon, C. H., Lee, E. S., Lim, D. S. and Bae, Y. S., PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53. Proc. Natl. Acad. Sci. USA 2009. 106: 7852-7857.
39. Yoon, C. H., Miah, M. A., Kim, K. P. and Bae, Y. S., New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase triggers Cdc2 polyubiquitination and G2 arrest under genotoxic stresses. EMBO Rep. 2010. 11: 393-399.
40. Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H. I., Antonia, S., Altiok, S. et al., Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 2010. 120: 1111-1124.
41. Russell, J. H. and Ley, T. J., Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 2002. 20: 323-370.